<p>Pictet Asset Management Holding SA 在最近向美國證券交易委員會（SEC）披露的文件中表示，其在達維塔公司（NYSE:DVA - 免費報告）的持股在第四季度減少了 69.2%。該基金在此期間出售了 17,018 股後，持有 7,558 股達維塔的股票。根據其最近的 SEC 文件，Pictet Asset Management Holding SA 在達維塔的持股價值為 859,000 美元。</p>
<ul>
<li>伯克希爾哈撒韋在巴菲特最後一個季度的表現</li>
</ul>
<p>其他大型投資者最近也調整了對該公司的持股。Elevation Wealth Partners LLC 在第四季度將其在達維塔的股份增加了 147.3%。Elevation Wealth Partners LLC 目前持有 277 股達維塔的股票，價值 31,000 美元，此前在上個季度又增持了 165 股。加拿大養老金計劃投資委員會在第二季度購買了達維塔的新股份，價值 43,000 美元。iSAM Funds UK Ltd 在第三季度購買了達維塔的新股份，價值 46,000 美元。Stance Capital LLC 在第三季度購買了達維塔的新股份，價值 47,000 美元。最後，Smartleaf Asset Management LLC 在第三季度將其在達維塔的股份增加了 34.9%。Smartleaf Asset Management LLC 目前持有 452 股達維塔的股票，價值 59,000 美元，此前在上個季度又增持了 117 股。機構投資者持有該公司 90.12% 的股票。</p>
<h2>華爾街分析師預測增長</h2>
<p>DVA 成為多份分析師報告的主題。Zacks Research 在 4 月 6 日的研究報告中將達維塔的股票評級從 “強力買入” 下調至 “持有”。瑞銀集團在 2 月 4 日的研究報告中將達維塔的目標價從 186.00 美元上調至 190.00 美元，並給予該股票 “買入” 評級。德意志銀行在週三的研究報告中將達維塔的評級從 “持有” 上調至 “買入”，並將該股票的目標價從 126.00 美元上調至 220.00 美元。Wall Street Zen 在 2 月 21 日的研究報告中將達維塔的評級從 “持有” 上調至 “買入”。最後，TD Cowen 在 2 月 3 日的研究報告中重申了對達維塔的 “持有” 評級。兩位分析師給予該股票 “買入” 評級，五位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，達維塔目前的共識評級為 “持有”，平均目標價為 166.50 美元。</p>
<ul>
<li>巴菲特最新的投資組合變動，以及另一隻秘密股票</li>
</ul>
<p><strong>查看我們對達維塔的最新分析</strong></p>
<h2>達維塔新聞摘要</h2>
<p>以下是本週影響達維塔的主要新聞：</p>
<ul>
<li>積極情緒：第一季度超預期：達維塔報告調整後的每股收益為 2.87 美元，收入為 34.2 億美元，超出市場共識，並顯示出同比收入增長和利潤率擴張——這是推動股價上漲的關鍵因素。達維塔 2026 年第一季度業績</li>
<li>積極情緒：指引上調：管理層將 2026 財年調整後的每股收益指引上調至 14.100–15.200 的區間，略高於/與市場預期一致——這降低了全年利潤的不確定性，並支持市盈率擴張。達維塔上調年度利潤預測</li>
<li>積極情緒：資本回報和投資者信心：公司披露了持續的股票回購（在本季度的回購和到 5 月 5 日的額外回購），這支持了每股收益和投資者情緒；異常的期權活動（大量看漲期權交易）表明了看漲的市場定位。Quiver Quantitative 分析</li>
<li>中性情緒：投資者接觸——管理層參與美銀健康會議（5 月 12 日）為投資者提供了另一個獲取指引和問答的場所；根據評論可能進一步影響情緒。達維塔將參加美銀 2026 年健康護理會議</li>
<li>中性情緒：分析師活動：德意志銀行重申/給予 “買入” 評級，並設定更高的 220 美元目標，而其他機構的看法各異——積極的分析師評論可以強化漲幅，但覆蓋情況不一。Quiver Quantitative 分析</li>
<li>消極情緒：機構/內部人士拋售：大型機構減持和顯著的內部人士銷售（包括與伯克希爾相關的過去銷售）如果持續將成為潛在的阻力。Quiver Quantitative 分析</li>
<li>消極情緒：盈利能力指標混合：儘管利潤率改善，但一些指標（報告的歷史負淨資產收益率）和對報銷動態的依賴仍然是長期風險，投資者可能在初次上漲後重新評估。MarketBeat DVA 概況</li>
</ul>
<h2>達維塔股價上漲 22.6%</h2>
<ul>
<li>華爾街對這兩隻上半年贏家持謹慎態度</li>
</ul>
<p>NYSE:DVA 週四開盤價為 192.49 美元。該股票的市值為 128.6 億美元，市盈率為 17.86，PEG 比率為 0.55，貝塔值為 0.84。該公司有 50 日簡單移動平均線為 152.12 美元，200 日簡單移動平均線為 132.20 美元。達維塔的 12 個月低點為 101.00 美元，12 個月高點為 194.29 美元。</p>
<p>達維塔（NYSE:DVA - 獲取免費報告）在 5 月 5 日星期二發佈了季度財報。該公司報告季度每股收益為 2.87 美元，超出分析師的共識預期 2.33 美元，超出 0.54 美元。該業務在本季度的收入為 34.2 億美元，而分析師的預期為 33.6 億美元。達維塔的淨利潤率為 5.65%，負淨資產收益率為 325.68%。該業務的季度收入同比增長 6.0%。去年同期，該公司每股收益為 2.00 美元。達維塔已將其 2026 財年的指引設定為 14.100-15.200 每股收益。股票分析師預測達維塔將在當前財年發佈 14.16 美元的每股收益。</p>
<h2>達維塔簡介</h2>
<p>（免費報告）</p>
<p>達維塔公司（DaVita Inc，NYSE: DVA）是領先的腎臟護理服務提供商，專注於為慢性腎衰竭和終末期腎病患者管理和運營門診透析中心。公司總部位於科羅拉多州丹佛，提供全面的治療方案，包括中心血液透析、腹膜透析和家庭透析治療。除了核心的透析服務外，達維塔還提供患者教育、營養諮詢、血管通路管理及相關實驗室服務，以支持腎臟健康和整體患者福祉。</p>
<p>自 1990 年代中期通過臨牀管理服務的分拆成立以來，達維塔通過有機增長以及戰略合作和收購不斷擴展。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過達維塔</li>
</ul>
<p><strong>想看看其他對 DVA 感興趣的對沖基金持有什麼？</strong> 請訪問 HoldingsChannel.com，獲取達維塔公司（NYSE:DVA - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 到達維塔嗎？</h2>
<p>在考慮達維塔之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而達維塔並不在名單上。</p>
<p>雖然達維塔目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

達維塔保健

<p>Pictet Asset Management Holding SA 已將其在 DaVita Inc. 的持股比例減少了 69.2%，在第四季度出售了 17,018 股，剩餘 7,558 股，價值 859,000 美元。其他投資者，包括 Elevation Wealth Partners 和加拿大養老金計劃投資委員會，也調整了他們的持股。DaVita 的股票獲得了分析師的褒貶不一的評級，普遍評級為 “持有”，目標價格為 166.50 美元。該公司報告了強勁的第一季度業績，提高了 2026 財年的每股收益指引，但面臨機構拋售和盈利指標不一的挑戰</p>

<p>Pictet Asset Management Holding SA lowered its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 69.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,558 shares of the company's stock after selling 17,018 shares during the period. Pictet Asset Management Holding SA's holdings in DaVita were worth $859,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Pictet Asset Management Holding SA 在最近向美國證券交易委員會（SEC）披露的文件中表示，其在達維塔公司（NYSE:DVA - 免費報告）的持股在第四季度減少了 69.2%。該基金在此期間出售了 17,018 股後，持有 7,558 股達維塔的股票。根據其最近的 SEC 文件，Pictet Asset Management Holding SA 在達維塔的持股價值為 859,000 美元。</p>
</div><ul>
<li>How Berkshire Hathaway Performed During Buffett's Final Quarter</li>
</ul>
<div class="lb-trans"><ul>
<li>伯克希爾哈撒韋在巴菲特最後一個季度的表現</li>
</ul>
</div><p>Other large investors have also recently modified their holdings of the company. Elevation Wealth Partners LLC raised its stake in shares of DaVita by 147.3% during the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company's stock valued at $31,000 after acquiring an additional 165 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in shares of DaVita during the second quarter valued at $43,000. iSAM Funds UK Ltd bought a new position in DaVita during the third quarter worth $46,000. Stance Capital LLC bought a new position in DaVita during the third quarter worth $47,000. Finally, Smartleaf Asset Management LLC raised its stake in DaVita by 34.9% during the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company's stock worth $59,000 after buying an additional 117 shares during the last quarter. Institutional investors own 90.12% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投資者最近也調整了對該公司的持股。Elevation Wealth Partners LLC 在第四季度將其在達維塔的股份增加了 147.3%。Elevation Wealth Partners LLC 目前持有 277 股達維塔的股票，價值 31,000 美元，此前在上個季度又增持了 165 股。加拿大養老金計劃投資委員會在第二季度購買了達維塔的新股份，價值 43,000 美元。iSAM Funds UK Ltd 在第三季度購買了達維塔的新股份，價值 46,000 美元。Stance Capital LLC 在第三季度購買了達維塔的新股份，價值 47,000 美元。最後，Smartleaf Asset Management LLC 在第三季度將其在達維塔的股份增加了 34.9%。Smartleaf Asset Management LLC 目前持有 452 股達維塔的股票，價值 59,000 美元，此前在上個季度又增持了 117 股。機構投資者持有該公司 90.12% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>DVA has been the subject of a number of analyst reports. Zacks Research downgraded shares of DaVita from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, April 6th. UBS Group lifted their target price on shares of DaVita from $186.00 to $190.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a &#34;hold&#34; rating to a &#34;buy&#34; rating and lifted their target price for the stock from $126.00 to $220.00 in a research note on Wednesday. Wall Street Zen raised shares of DaVita from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, February 21st. Finally, TD Cowen reissued a &#34;hold&#34; rating on shares of DaVita in a research note on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DaVita presently has a consensus rating of &#34;Hold&#34; and an average price target of $166.50.</p>
<div class="lb-trans"><p>DVA 成為多份分析師報告的主題。Zacks Research 在 4 月 6 日的研究報告中將達維塔的股票評級從 “強力買入” 下調至 “持有”。瑞銀集團在 2 月 4 日的研究報告中將達維塔的目標價從 186.00 美元上調至 190.00 美元，並給予該股票 “買入” 評級。德意志銀行在週三的研究報告中將達維塔的評級從 “持有” 上調至 “買入”，並將該股票的目標價從 126.00 美元上調至 220.00 美元。Wall Street Zen 在 2 月 21 日的研究報告中將達維塔的評級從 “持有” 上調至 “買入”。最後，TD Cowen 在 2 月 3 日的研究報告中重申了對達維塔的 “持有” 評級。兩位分析師給予該股票 “買入” 評級，五位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，達維塔目前的共識評級為 “持有”，平均目標價為 166.50 美元。</p>
</div><ul>
<li>Buffett's Latest Portfolio Moves, and Another Secret Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>巴菲特最新的投資組合變動，以及另一隻秘密股票</li>
</ul>
</div><p><strong>View Our Latest Analysis on DaVita</strong></p>
<div class="lb-trans"><p><strong>查看我們對達維塔的最新分析</strong></p>
</div><h2>DaVita News Summary</h2>
<div class="lb-trans"><h2>達維塔新聞摘要</h2>
</div><p>Here are the key news stories impacting DaVita this week:</p>
<div class="lb-trans"><p>以下是本週影響達維塔的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Q1 beat: DaVita reported adjusted EPS of $2.87 and revenue of $3.42B, topping consensus and showing year‑over‑year revenue growth and margin expansion — a key driver of the rally. DaVita Inc. 1st Quarter 2026 Results</li>
<li>Positive Sentiment: Guidance raise: Management lifted FY2026 adjusted EPS guidance to a range of 14.100–15.200, slightly above/consistent with street expectations — this reduces uncertainty on full‑year profits and supports multiple expansion. DaVita lifts annual profit forecast</li>
<li>Positive Sentiment: Capital returns and investor confidence: Company disclosed ongoing buybacks (repurchases during the quarter and additional repurchases through May 5), which supports EPS and investor sentiment; unusual option activity (large call volume) indicates bullish positioning. Quiver Quantitative analysis</li>
<li>Neutral Sentiment: Investor access — management participation at BofA Healthcare Conference (May 12) gives investors another venue for guidance color and Q&amp;A; could further influence sentiment depending on commentary. DaVita to Participate in BofA 2026 Health Care Conference</li>
<li>Neutral Sentiment: Analyst activity: Deutsche Bank reiterated/issued a Buy and set a higher $220 target while other houses vary — positive analyst commentary can reinforce gains but coverage is mixed. Quiver Quantitative analysis</li>
<li>Negative Sentiment: Institutional/insider selling: Large institutional reductions and notable insider sales (including past sales by Berkshire-related positions) are a potential headwind if sustained. Quiver Quantitative analysis</li>
<li>Negative Sentiment: Profitability metrics mixed: despite margin improvement, some metrics (reported negative historical ROE) and reliance on reimbursement dynamics remain longer‑term risks investors may reassess after the initial rally. MarketBeat DVA profile</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：第一季度超預期：達維塔報告調整後的每股收益為 2.87 美元，收入為 34.2 億美元，超出市場共識，並顯示出同比收入增長和利潤率擴張——這是推動股價上漲的關鍵因素。達維塔 2026 年第一季度業績</li>
<li>積極情緒：指引上調：管理層將 2026 財年調整後的每股收益指引上調至 14.100–15.200 的區間，略高於/與市場預期一致——這降低了全年利潤的不確定性，並支持市盈率擴張。達維塔上調年度利潤預測</li>
<li>積極情緒：資本回報和投資者信心：公司披露了持續的股票回購（在本季度的回購和到 5 月 5 日的額外回購），這支持了每股收益和投資者情緒；異常的期權活動（大量看漲期權交易）表明了看漲的市場定位。Quiver Quantitative 分析</li>
<li>中性情緒：投資者接觸——管理層參與美銀健康會議（5 月 12 日）為投資者提供了另一個獲取指引和問答的場所；根據評論可能進一步影響情緒。達維塔將參加美銀 2026 年健康護理會議</li>
<li>中性情緒：分析師活動：德意志銀行重申/給予 “買入” 評級，並設定更高的 220 美元目標，而其他機構的看法各異——積極的分析師評論可以強化漲幅，但覆蓋情況不一。Quiver Quantitative 分析</li>
<li>消極情緒：機構/內部人士拋售：大型機構減持和顯著的內部人士銷售（包括與伯克希爾相關的過去銷售）如果持續將成為潛在的阻力。Quiver Quantitative 分析</li>
<li>消極情緒：盈利能力指標混合：儘管利潤率改善，但一些指標（報告的歷史負淨資產收益率）和對報銷動態的依賴仍然是長期風險，投資者可能在初次上漲後重新評估。MarketBeat DVA 概況</li>
</ul>
</div><h2>DaVita Trading Up 22.6%</h2>
<div class="lb-trans"><h2>達維塔股價上漲 22.6%</h2>
</div><ul>
<li>Wall Street Is Cautious on These 2 First Half Winners</li>
</ul>
<div class="lb-trans"><ul>
<li>華爾街對這兩隻上半年贏家持謹慎態度</li>
</ul>
</div><p>NYSE:DVA opened at $192.49 on Thursday. The stock has a market capitalization of $12.86 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 0.55 and a beta of 0.84. The firm has a fifty day simple moving average of $152.12 and a two-hundred day simple moving average of $132.20. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $194.29.</p>
<div class="lb-trans"><p>NYSE:DVA 週四開盤價為 192.49 美元。該股票的市值為 128.6 億美元，市盈率為 17.86，PEG 比率為 0.55，貝塔值為 0.84。該公司有 50 日簡單移動平均線為 152.12 美元，200 日簡單移動平均線為 132.20 美元。達維塔的 12 個月低點為 101.00 美元，12 個月高點為 194.29 美元。</p>
</div><p>DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts' consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion during the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 325.68%. The business's quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the company posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts predict that DaVita Inc. will post 14.16 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>達維塔（NYSE:DVA - 獲取免費報告）在 5 月 5 日星期二發佈了季度財報。該公司報告季度每股收益為 2.87 美元，超出分析師的共識預期 2.33 美元，超出 0.54 美元。該業務在本季度的收入為 34.2 億美元，而分析師的預期為 33.6 億美元。達維塔的淨利潤率為 5.65%，負淨資產收益率為 325.68%。該業務的季度收入同比增長 6.0%。去年同期，該公司每股收益為 2.00 美元。達維塔已將其 2026 財年的指引設定為 14.100-15.200 每股收益。股票分析師預測達維塔將在當前財年發佈 14.16 美元的每股收益。</p>
</div><h2>DaVita Profile</h2>
<div class="lb-trans"><h2>達維塔簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.</p>
<div class="lb-trans"><p>達維塔公司（DaVita Inc，NYSE: DVA）是領先的腎臟護理服務提供商，專注於為慢性腎衰竭和終末期腎病患者管理和運營門診透析中心。公司總部位於科羅拉多州丹佛，提供全面的治療方案，包括中心血液透析、腹膜透析和家庭透析治療。除了核心的透析服務外，達維塔還提供患者教育、營養諮詢、血管通路管理及相關實驗室服務，以支持腎臟健康和整體患者福祉。</p>
</div><p>Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.</p>
<div class="lb-trans"><p>自 1990 年代中期通過臨牀管理服務的分拆成立以來，達維塔通過有機增長以及戰略合作和收購不斷擴展。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than DaVita</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過達維塔</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding DVA?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 DVA 感興趣的對沖基金持有什麼？</strong> 請訪問 HoldingsChannel.com，獲取達維塔公司（NYSE:DVA - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURWQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DVA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DaVita Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 到達維塔嗎？</h2>
</div><p>Before you consider DaVita, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮達維塔之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而達維塔並不在名單上。</p>
</div><p>While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然達維塔目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Pictet Asset Management Holding SA Sells 17,018 Shares of DaVita Inc. $DVA

Market Beat

伯克希爾哈撒韋-A

伯克希爾哈撒韋-B

瑞銀集團

德意志銀行

美國銀行

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

百達資產管理控股公司出售了 17,018 股達維塔公司（DaVita Inc.）的股票 $DVA